Pharmaceuticals

Global Orphan Drugs Service Industry Trends: Where the Market Is Headed by 2029

November 21, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Orphan Drugs Service Market Size Likely To Evolve From 2025 Through 2034?

The orphan drugs service market has witnessed rapid expansion in recent years. Its size is expected to increase from $37.05 billion in 2024 to $43.40 billion in 2025, reflecting a compound annual growth rate (CAGR) of 17.1%. The expansion observed historically can be attributed to the rising prevalence of rare diseases, increasing government support, expanding initiatives by patient advocacy groups, a heightened focus on unmet medical needs, and growing collaboration between healthcare providers and researchers.

The orphan drugs service market size is projected for significant expansion in the coming years. This market is set to reach $80.62 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 16.7%. The anticipated growth during this period is driven by factors such as enhanced investment in biopharmaceutical research, increasing demand for precision medicine, wider adoption of sophisticated clinical trial designs, a surge in funding from venture capital firms, and a heightened focus on harmonizing global regulations. Key trends anticipated for the forecast period encompass technological progress in drug discovery platforms, advancements in cell and gene therapy services, significant investment in artificial intelligence for clinical trials, evolution in biomarker-based patient selection methodologies, and novel approaches to integrating digital health for patient surveillance.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28287&type=smp

Which Drivers Are Shaping The Orphan Drugs Service Industry’s Market Share?

The orphan drugs service market is projected to expand due to increasing investment in rare diseases. A rare disease is defined as a medical condition impacting a small fraction of the population, specifically fewer than 1 in 2,000 individuals, often being chronic, progressive, and potentially life-threatening or debilitating. This investment is mainly spurred by the growing awareness of unmet medical requirements and the prospect of significant returns through regulatory benefits like orphan drug designation, market exclusivity, and reduced development expenses. Increased investment in rare diseases improves orphan drug services by boosting funding for research and development, enabling the creation of treatments for conditions previously overlooked. It also speeds up drug accessibility by facilitating clinical trials, regulatory approvals, and patient access, thereby enhancing treatment options for those with rare diseases. For instance, in April 2024, Global Genes, a US-based nonprofit organization, reported that companies engaged in developing drugs for rare diseases secured $7.1 billion in the first quarter of 2024, representing a 307% surge compared to the $1.8 billion raised during the same period in 2023. Consequently, the rising investment in rare diseases is a key factor propelling the expansion of the orphan drugs service market.

What Are The Primary Types Of Segments Analyzed In The Orphan Drugs Service Market?

The orphan drugs service market covered in this report is segmented as

1) By Type: Congenital Disease, Genetic Disease, Tumors And Cancer, Chronic, Other Types

2) By Therapeutic Area: Oncology, Metabolic Disorders, Neurological Disorders, Hematology, Infectious Diseases, Other Rare Diseases

3) By Application: Aldult, Children

Subsegments:

1) By Congenital Disease: Heart Defects, Cleft Lip And Palate, Spina Bifida, Down Syndrome

2) By Genetic Disease: Cystic Fibrosis, Huntington Disease, Sickle Cell Anemia, Muscular Dystrophy

3) By Tumors And Cancer: Leukemia, Lymphoma, Neuroblastoma, Sarcoma

4) By Chronic: Rare Metabolic Disorders, Rare Endocrine Disorders, Rare Cardiovascular Disorders, Rare Neurological Disorders

5) By Other Types: Rare Infectious Diseases, Rare Immunological Disorders, Rare Dermatological Conditions, Rare Ophthalmological Disorders

How Are Trends Influencing The Orphan Drugs Service Market?

Major companies within the orphan drugs service market are prioritizing the attainment of regulatory approvals to accelerate the creation and availability of treatments for uncommon diseases. These regulatory approvals represent formal authorizations from governmental bodies, permitting the legal testing, production, and sale of a drug or therapy for patient use. For example, in February 2023, Askbio GmbH, a US-based gene therapy firm, obtained orphan drug designation from the European Commission for AB-1003, an innovative investigational gene therapy designed for limb-girdle muscular dystrophy. This therapy, based on adeno-associated virus (AAV), seeks to restore the FKRP enzyme activity in muscle cells through a single intravenous infusion. AB-1003 has received orphan drug designation from both the European Commission and the U.S. Food and Drug Administration (FDA), alongside rare pediatric disease and fast track designations from the FDA, underscoring the pressing unmet medical requirements. It is presently undergoing a Phase 1/2 clinical trial (LION-CS101), assessing its safety and effectiveness in adults with genetically confirmed limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

Who Are The Core Companies Influencing The Orphan Drugs Service Market Landscape?

Major companies operating in the orphan drugs service market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, AstraZeneca PLC, The Bristol-Myers Squibb Company, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., IQVIA Inc., CSL Behring GmbH, Lonza Group AG, BioMarin Pharmaceutical Inc., Fortrea Holdings Inc., Medpace Inc., Sarepta Therapeutics, Caidya Inc., and Cevidra Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/orphan-drugs-service-global-market-report

Which Region Is Projected To Lead The Orphan Drugs Service Market During The Forecast Period?

North America was the largest region in the orphan drugs service market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in orphan drugs service report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Orphan Drugs Service Market Report:

https://www.thebusinessresearchcompany.com/customise?id=28287&type=smp

Browse Through More Reports Similar to the Global Orphan Drugs Service Market 2025, By The Business Research Company

Drug Discovery Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drug-discovery-services-global-market-report

Child And Youth Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/child-and-youth-services-global-market-report

Pharmaceuticals Market 2025

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795